<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cytokines and inflammation</journal-id><journal-title-group><journal-title xml:lang="en">Cytokines and inflammation</journal-title><trans-title-group xml:lang="ru"><trans-title>Цитокины и воспаление</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1684-7849</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">689067</article-id><article-id pub-id-type="doi">10.17816/CI689067</article-id><article-id pub-id-type="edn">XFTAFJ</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Relationship between platelet-leukocyte aggregate levels and metabolic hormones in patients with chronic coronary heart disease: a cross-sectional study</article-title><trans-title-group xml:lang="ru"><trans-title>Взаимосвязь содержания тромбоцитарно-лейкоцитарных агрегатов с гормонами-регуляторами метаболизма у пациентов с хронической ишемической болезнью сердца: одномоментное исследование</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-7865-6948</contrib-id><contrib-id contrib-id-type="spin">8635-2098</contrib-id><name-alternatives><name xml:lang="en"><surname>Vyrostkova</surname><given-names>Alexandra I.</given-names></name><name xml:lang="ru"><surname>Выросткова</surname><given-names>Александра Игоревна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alexandra.vy20@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4537-0008</contrib-id><contrib-id contrib-id-type="spin">6987-2021</contrib-id><name-alternatives><name xml:lang="en"><surname>Kologrivova</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Кологривова</surname><given-names>Ирина Вячеславовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>ikologrivova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9645-6720</contrib-id><contrib-id contrib-id-type="spin">9588-9414</contrib-id><name-alternatives><name xml:lang="en"><surname>Suslova</surname><given-names>Tatiana E.</given-names></name><name xml:lang="ru"><surname>Суслова</surname><given-names>Татьяна Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>tes@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6679-1269</contrib-id><contrib-id contrib-id-type="spin">3093-4903</contrib-id><name-alternatives><name xml:lang="en"><surname>Koshelskaya</surname><given-names>Olga A.</given-names></name><name xml:lang="ru"><surname>Кошельская</surname><given-names>Ольга Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>koshel@live.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1235-9956</contrib-id><contrib-id contrib-id-type="spin">9385-8321</contrib-id><name-alternatives><name xml:lang="en"><surname>Kravchenko</surname><given-names>Elena S.</given-names></name><name xml:lang="ru"><surname>Кравченко</surname><given-names>Елена Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>nikonovaes@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6924-966X</contrib-id><contrib-id contrib-id-type="spin">3698-9862</contrib-id><name-alternatives><name xml:lang="en"><surname>Dmitriukov</surname><given-names>Alexey A.</given-names></name><name xml:lang="ru"><surname>Дмитрюков</surname><given-names>Алексей Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>aldmn9k@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Tomsk National Research Medical Center of the Russian Academy of Sciences, Cardiology Research Institute</institution></aff><aff><institution xml:lang="ru">Томский национальный исследовательский медицинский центр Российской академии наук, Научно-исследовательский институт кардиологии</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-12-17" publication-format="electronic"><day>17</day><month>12</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-12-25" publication-format="electronic"><day>25</day><month>12</month><year>2025</year></pub-date><volume>22</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>118</fpage><lpage>127</lpage><history><date date-type="received" iso-8601-date="2025-08-12"><day>12</day><month>08</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-12-10"><day>10</day><month>12</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Vyrostkova A.I., Kologrivova I.V., Suslova T.E., Koshelskaya O.A., Kravchenko E.S., Dmitriukov A.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Выросткова А.И., Кологривова И.В., Суслова Т.Е., Кошельская О.А., Кравченко Е.С., Дмитрюков А.А.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Vyrostkova A.I., Kologrivova I.V., Suslova T.E., Koshelskaya O.A., Kravchenko E.S., Dmitriukov A.A.</copyright-holder><copyright-holder xml:lang="ru">Выросткова А.И., Кологривова И.В., Суслова Т.Е., Кошельская О.А., Кравченко Е.С., Дмитрюков А.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-12-25"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://cijournal.ru/1684-7849/article/view/689067">https://cijournal.ru/1684-7849/article/view/689067</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND: </bold>Chronic coronary heart disease (CHD) is accompanied by low-grade inflammation, with platelet-leukocyte aggregates (PLAs) being important mediators. Their formation may depend on many factors, but the relationship between PLAs and metabolic hormones in coronary atherosclerosis (CA) of different severity has been understudied.</p> <p><bold>AIM: </bold>To study the relationship between PLA levels and basal and postprandial levels of hormones in patients with CHD based on the CA severity.</p> <p><bold>METHODS: </bold>The study included 32 patients with chronic CHD grouped based on the CA severity by the median Gensini Score index, a group with more severe CA (GS ≥ 42.5; <italic>n</italic> = 18) and less severe CA (GS &lt; 42.5; <italic>n</italic> = 14). Blood PLAs were determined by flow cytometry with visualization. Insulin, C-peptide, glucagon, glucagon-like peptide-1 (GLP-1), and leptin were measured by multiplexed immunoassay.</p> <p><bold>RESULTS: </bold>Patients with GS ≥ 42.5 demonstrated an increased proportion of lymphocyte aggregates with more than three platelets [0.6 (0.3; 1.6) vs 0.1 (0.0; 0.5)%, <italic>p</italic> = 0.042] and a lower basal glucagon [25.9 (16.9; 47.2) vs 57.9 (23.2; 69.3) pg/mL, <italic>p</italic> = 0.049] than patients with GS &lt; 42.5. PLAs correlated only with postprandial hormone levels, whereas these relationships were determined by the severity of atherosclerosis. Thus, in patients with GS &lt; 42.5, negative relationships were found between the level of GLP-1 and CD62P<sup>+</sup>-PLA (<italic>r</italic><sub>s</sub> = −0.850; <italic>p</italic> = 0.004 and <italic>r</italic><sub>s</sub> = −0.733; <italic>p</italic> = 0.024), insulin and the proportion of large platelete-mononuclear leukocyte aggregates (<italic>r</italic><sub>s</sub> = −0.750; <italic>p</italic> = 0.020 and <italic>r</italic><sub>s</sub> = −0.766; <italic>p</italic> = 0.016), and positive relationships were found between leptin and the proportion of small PLAs (<italic>r</italic><sub>s</sub> = 0.700; <italic>p</italic> = 0.036 and <italic>r</italic><sub>s</sub> = 0.753; <italic>p</italic> = 0.019). In patients with GS ≥ 42.5, positive relationship was recorded between the level of GLP-1 and CD62P<sup>+</sup>-PLA (<italic>r</italic><sub>s</sub> = 0.636; <italic>p</italic> = 0.045), whereas leptin positively correlated with the proportion of large PLAs (<italic>r</italic><sub>s</sub> = 0.663; <italic>p</italic> = 0.037 and <italic>r</italic><sub>s</sub> = 0.657; <italic>p</italic> = 0.039).</p> <p><bold>CONCLUSION: </bold>The study was the first to show a relationship between PLAs and postprandial hormone levels in patients with chronic CHD. The findings indicate the need for further research into the role of PLAs and hormones in immune inflammatory activity in patients with CHD.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Хроническая ишемическая болезнь сердца (ИБС) сопровождается низкоинтенсивным воспалением, важными медиаторами которого являются тромбоцитарно-лейкоцитарные агрегаты (ТЛА). Их формирование может зависеть от многих факторов, однако взаимосвязь ТЛА с содержанием гормонов — регуляторов метаболизма при различной степени выраженности коронарного атеросклероза (КА) — изучена недостаточно.</p> <p><bold>Цель исследования. </bold>Изучить взаимосвязи между содержанием ТЛА с базальными и постпрандиальными концентрациями гормонов у пациентов с хронической ИБС в зависимости от степени выраженности коронарного атеросклероза.</p> <p><bold>Методы. </bold>В исследование включены 32 пациента с хронической ИБС, разделённые на группы в зависимости от выраженности КА по медиане индекса Gensini Score: группа с более выраженным КА (GS ≥ 42,5 балла; <italic>n</italic> = 18) и менее выраженным КА (GS &lt; 42,5 балла; <italic>n</italic> = 14). Содержание ТЛА в крови определяли методом проточной цитометрии с визуализацией. Концентрации инсулина, С-пептида, глюкагона, глюкагоноподобного пептида-1 (ГПП-1) и лептина оценивали методом мультиплексного иммуноанализа.</p> <p><bold>Результаты. </bold>У пациентов с GS ≥ 42,5 балла наблюдали повышение доли агрегатов лимфоцитов с более чем тремя тромбоцитами [0,6 (0,3; 1,6) против 0,1 (0,0; 0,5) %, <italic>p</italic> = 0,042], а также более низкое базальное содержание глюкагона [25,9 (16,9; 47,2) против 57,9 (23,2; 69,3) пг/мл, <italic>p</italic> = 0,049] по сравнению с пациентами с GS &lt; 42,5 балла. Содержание ТЛА коррелировало исключительно с постпрандиальной концентрацией гормонов, при этом характер выявленных связей зависел от степени выраженности атеросклероза. Так, у пациентов с GS &lt; 42,5 балла обнаружены отрицательные взаимосвязи между концентрацией ГПП-1 и CD62P<sup>+</sup>-ТЛА (<italic>r</italic><sub>s</sub> = −0,850; <italic>p</italic> = 0,004 и <italic>r</italic><sub>s</sub> = −0,733; <italic>p</italic> = 0,024); между концентрацией инсулина и долей крупных агрегатов мононуклеарных лейкоцитов с тромбоцитами (<italic>r</italic><sub>s</sub> = −0,750; <italic>p</italic> = 0,020 и <italic>r</italic><sub>s</sub> = −0,766; <italic>p</italic> = 0,016), а также положительные взаимосвязи между концентрацией лептина и долей мелких ТЛА (<italic>r</italic><sub>s</sub> = 0,700; <italic>p</italic> = 0,036 и <italic>r</italic><sub>s</sub> = 0,753; <italic>p</italic> = 0,019). У пациентов с GS ≥ 42,5 балла зафиксирована положительная взаимосвязь между концентрацией ГПП-1 и содержанием CD62P<sup>+</sup>-ТЛА (<italic>r</italic><sub>s</sub> = 0,636; <italic>p</italic> = 0,045); концентрация лептина положительно коррелировала с долей крупных ТЛА (<italic>r</italic><sub>s</sub> = 0,663; <italic>p</italic> = 0,037 и <italic>r</italic><sub>s</sub> = 0,657; <italic>p</italic> = 0,039).</p> <p><bold>Заключение. </bold>Впервые продемонстрирована взаимосвязь между содержанием ТЛА с постпрандиальными концентрациями гормонов у пациентов с хронической ИБС. Результаты указывают на необходимость дальнейшего изучения роли ТЛА и гормонов в иммуновоспалительных процессах при ИБС.</p></trans-abstract><kwd-group xml:lang="en"><kwd>platelet-leukocyte aggregates</kwd><kwd>flow cytometry with visualization</kwd><kwd>hormones</kwd><kwd>atherosclerosis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>тромбоцитарно-лейкоцитарные агрегаты</kwd><kwd>проточная цитометрия с визуализацией</kwd><kwd>гормоны</kwd><kwd>атеросклероз</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Правительство Российской Федерации</institution></institution-wrap><institution-wrap><institution xml:lang="en">Government of the Russian Federation</institution></institution-wrap></funding-source><award-id>122020300043-1</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Hu B, Wang Y, Chen D, et al. Temporal trends in the prevalence and death of ischemic heart disease in women of childbearing age from 1990 to 2019: a multilevel analysis based on the Global burden of disease study 2019. Front Cardiovasc Med. 2024;11:1366832. doi: 10.3389/fcvm.2024.1366832 EDN: TIOCNZ</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Pluta K, Porębska K, Urbanowicz T, et al. Platelet-leucocyte aggregates as novel biomarkers in cardiovascular diseases. Biology. 2022;11(2):224. doi: 10.3390/biology11020224</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Hottz ED, Quirino-Teixeira AC, Merij LB, et al. Platelet-leukocyte interactions in the pathogenesis of viral infections. Platelets. 2022;33(2):200–207. doi: 10.1080/09537104.2021.1952179 EDN: BMRQFG</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Zahran AM, El-Badawy O, Mohamad IL, et al. Platelet activation and platelet-leukocyte aggregates in type I diabetes mellitus. Clin Appl Thromb Hemost. 2018;24(9_suppl):230S–239S. doi: 10.1177/1076029618805861</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Allen N, Barrett TJ, Guo Y, et al. Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease. Atherosclerosis. 2019;282:11–18. doi: 10.1016/j.atherosclerosis.2018.12.029</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Trubacheva OA, Petrova IV, Kologrivova IV, et al. Mechanism of collagen-induced platelet aggregation in patients with impaired carbohydrate tolerance or type 2 diabetes mellitus in combination with arterial hypertension. The Siberian medical journal. 2019;34(4):112–117. doi: 10.29001/2073-8552-2019-34-4-112-117 EDN: UEGHWY</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Osaka N, Kushima H, Mori Y, et al. Anti-inflammatory and atheroprotective properties of glucagon. Diab Vasc Dis Res. 2020;17(5):1479164120965183. doi: 10.1177/1479164120965183 EDN: TLRPOL</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Sternkopf M, Nagy M, Baaten CCFMJ, et al. Native, intact glucagon-like peptide 1 is a natural suppressor of thrombus growth under physiological flow conditions. Arterioscler Thromb Vasc Biol. 2020;40(3):e65–e77. doi: 10.1161/ATVBAHA.119.313645 EDN: LOBMJW</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>DiNicolantonio JJ, Bhutani J, OKeefe JH, Crofts C. Postprandial insulin assay as the earliest biomarker for diagnosing pre-diabetes, type 2 diabetes and increased cardiovascular risk. Open Heart. 2017;4(2):e000656. doi: 10.1136/openhrt-2017-000656</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Nagasawa A, Matsuno K, Tamura S, et al. The basis examination of leukocyte-platelet aggregates with CD45 gating as a novel platelet activation marker. Int J Lab Hematol. 2013;35(5):534–541. doi: 10.1111/ijlh.12051</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hui H, Fuller KA, Erber WN, Linden MD. Imaging flow cytometry in the assessment of leukocyte-platelet aggregates. Methods. 2017;112:46–54. doi: 10.1016/j.ymeth.2016.10.002</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kologrivova IV, Suslova TE, Vyrostkova AI, et al. The size of platelet-leukocyte aggregates in patients with various degree of coronary atherosclerosis. Medical Immunology (Russia). doi: 10.15789/1563-0625-TSO-2960</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Abdel-Moneim A, Mahmoud B, Sultan EA, Mahmoud R. Relationship of leukocytes, platelet indices and adipocytokines in metabolic syndrome patients. Diabetes Metab Syndr. 2019;13(1):874–880. doi: 10.1016/j.dsx.2018.12.016</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ozata M, Avcu F, Durmus O, et al. Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency. Obes Res. 2001;9(10):627–630. doi: 10.1038/oby.2001.82</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Santos-Alvarez J, Goberna R, Sánchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol. 1999;194(1):6–11. doi: 10.1006/cimm.1999.1490</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Hong JH, Kim DH, Lee MK. Glucolipotoxicity and GLP-1 secretion. BMJ Open Diabetes Res Care. 2021;9(1):e001905. doi: 10.1136/bmjdrc-2020-001905 EDN: ZFVFPJ</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Steven S, Jurk K, Kopp M, et al. Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice. Br J Pharmacol. 2017;174(12):1620–1632.doi: 10.1111/bph.13549</mixed-citation></ref></ref-list></back></article>
